Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat single-dose crossover study in Raynaud's phenomenon
2013-001899-38Phase 2Completed
- Sponsor
- Bayer
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of riociguat in Raynaud disease (2 arms), sponsored by Bayer. Primary endpoints: Safety and tolerability and Pharmacodynamics. Started Jul 2013; status: completed.
02
Drugs
riociguat
03
Conditions
Raynaud disease
Beyond the preview
Go deeper on 2013-001899-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001899-38.